Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Galina, Salogub"'
Autor:
Max Topp, Monika Dlugosz-Danecka, Aleksander B. Skotnicki, Galina Salogub, Andreas Viardot, Andreas K. Klein, Georg Hess, Christian S. Michel, Sebastian Grosicki, Alex Gural, Sylvia E. Schwarz, Kerstin Pietzko, Ulrike Gärtner, András Strassz, Leila Alland, Jiri Mayer
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background The prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin’s lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treat
Externí odkaz:
https://doaj.org/article/733ebcc0ead14adca31fae5c33809819
Autor:
Tatiana, Shtam, Stanislav, Naryzhny, Darya, Kulabukhova, Luiza, Garaeva, Konstantin, Senkevich, Sergey, Landa, Elena, Varfolomeeva, Galina, Salogub, Nikolai, Verlov, Arthur, Kopylov, Elena, Zorina, Roman, Kamyshinsky, Tatiana, Usenko, Alexander, Schwarzman, Ekaterina, Zakharova, Anton, Emelyanov, Sofya, Pchelina
Publikováno v:
In European Journal of Medical Genetics November 2020 63(11)
Autor:
Fredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Legiec, Luděk Pour, Ivan Špička, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimir Maisnar, Gábor Mikala, Laura Rosiñol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A Bakker, Roman Hájek, Maria-Victoria Mateos, Paul G Richardson, Pieter Sonneveld, Fredrik Schjesvold, Anna Nikolayeva, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Gabor Mikala, Laura Rosinol, Tatiana Konstantinova, Anargyros Symeonidis, Moshe Gatt, Arpad Illes, Haifaa Abdulhaq, Moez Dungarwalla, Sebastian Grosicki, Roman Hajek, Xavier Leleu, Alexander Myasnikov, Paul G. Richardson, Irit Avivi, Dries Deeren, Mercedes Gironella, Miguel Teodoro Hernandez-Garcia, Joaquin Martinez Lopez, Muriel Newinger-Porte, Paz Ribas, Olga Samoilova, Eric Voog, Mario Arnao-Herraiz, Estrella Carrillo-Cruz, Paolo Corradini, Jyothi Dodlapati, Miquel Granell Gorrochategui, Shang-Yi Huang, Matthew Jenner, Lionel Karlin, Jin Seok Kim, Agnieszka Kopacz, Nadezhda Medvedeva, Chang-Ki Min, Roberto Mina, Katrin Palk, Ho-Jin Shin, Sang Kyun Sohn, Jason Tache, Achilles Anagnostopoulos, Jose-Maria Arguiñano, Michele Cavo, Joanne Filicko, Margaret Garnes, Janusz Halka, Kathrin Herzog-Tzarfati, Natalia Ipatova, Kihyun Kim, Maria-Theresa Krauth, Irina Kryuchkova, Mihaela Cornelia Lazaroiu, Mario Luppi, Andrei Proydakov, Alessandro Rambaldi, Milda Rudzianskiene, Su-Peng Yeh, Maria Magdalena Alcalá-Peña, Adrian Alegre Amor, Hussain Alizadeh, Maurizio Bendandi, Gillian Brearton, Randall Brown, Jim Cavet, Najib Dally, Miklos Egyed, José Ángel Hernández-Rivas, Ain Kaare, Jean-Michel Karsenti, Janusz Kloczko, William Kreisle, Je-Jung Lee, Sigrid Machherndl-Spandl, Sudhir Manda, Ivan Moiseev, Jan Moreb, Zsolt Nagy, Santosh Nair, Albert Oriol-Rocafiguera, Michael Osswald, Paula Otero-Rodriguez, Valdas Peceliunas, Torben Plesner, Philippe Rey, Giuseppe Rossi, Don Stevens, Celia Suriu, Corrado Tarella, Anke Verlinden, Alain Zannetti
Publikováno v:
The Lancet Haematology, 9(2), e98-e110. Lancet Publishing Group
Digital.CSIC. Repositorio Institucional del CSIC
instname
Digital.CSIC. Repositorio Institucional del CSIC
instname
Background Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON study. We aimed to determine whether melflufen plus dexamethasone would provi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dc03258e4b4010f40b43625027ef43b
https://doi.org/10.1016/s2352-3026(21)00381-1
https://doi.org/10.1016/s2352-3026(21)00381-1
Autor:
Sonja Zweegman, Shanti Natarajan-Amé, Francesco Passamonti, Raajit K. Rampal, Moshe Talpaz, Daobin Zhou, Kelly McCaul, Mary Frances McMullin, Candido E. Rivera, Hiroshi Kawabata, Günther Gastl, H. Joachim Deeg, Heinz Gisslinger, Angela Hamblin, Vincent Ribrag, Reinier Raymakers, John Catalano, P. Mineur, Fabrizio Pane, Giuseppe Saglio, Jean Loup Demory, Josef T. Prchal, Qian Jiang, Kudrat Abdulkadyrov, Emmanuel C. Besa, Richard F. Schlenk, Gary J. Schiller, John T. Reilly, Adam J. Mead, Robert Peter Gale, William Stevenson, Gemma Buck, Kazuma Ohyashiki, Dominique Bordessoule, Mark Drummond, Jianyong Li, Ayalew Tefferi, Ting Liu, Tomoko Hata, Jianhua Zhong, Juan Carlos Hernandez Boluda, Damiano Rondelli, Norio Komatsu, John Mascarenhas, Zhixiang Shen, Timothy Devos, Alessandro M. Vannucchi, Katsuto Takenaka, Randall Brown, Haifa K. Al-Ali, Thomas J. Nevill, Jen Chin Wang, Daniel Tesfa, Jennifer O'Sullivan, Andrew Turner, Guanlin Wang, Galina Salogub, Claire N. Harrison, Dragana Milojkovic, Giovanni Barosi, James W. Vardiman, Peter A. W. te Boekhorst, Ruben A. Mesa, Jan Van Droogenbroeck, Manana Sokolova, Vikas Gupta, Lennart Nilsson, Andrey Zaritskiy, Nikolaos Barkas, Werner Linkesch, Mario Cazzola, Jean-Jacques Kiladjian, Ramon V. Tiu, Kiyoshi Ando, Onima Chowdhury, Emilio Ojeda, Martin Griesshammer, Christian Recher, Alessandro Rambaldi, Francisco Cervantes, Giorgina Specchia
Publikováno v:
Leukemia
for the RESUME trialists 2020, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia . https://doi.org/10.1038/s41375-020-0979-6, https://doi.org/10.1038/s41375-020-0979-6
Chowdhury, O, O’Sullivan, J, Barkas, N, Wang, G, Buck, G, Hamblin, A, Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, McMullin, M F, Zhong, J, Gale, R P, Mead, A J, Catalano, J, Stevenson, W, Gastl, G, Linkesch, W, Van Droogenbroeck, J, Mineur, P, Gupta, V, Turner, A, Nevill, T, Li, J, Shen, Z, Liu, T, Bordessoule, D, Natarajan-Amé, S, Recher, C, Demory, J L, Schlenk, R, Griesshammer, M, Cazzola, M, Saglio, G, Specchia, G, Rambaldi, A, Pane, F, Zweegman, S, te Boekhorst, P, Raymakers, R, Abdulkadyrov, K, Sokolova, M, Salogub, G, Zaritskiy, A, Cervantes, F, Boluda, J C H, Ojeda, E, Tesfa, D, Nilsson, L, Drummond, M, Reilly, J, Harrison, C, Milojkovic, D, Rivera, C, Besa, E, Deeg, H J, Mascarenhas, J, Prchal, J, Tiu, R, Talpaz, M, Wang, J C, Rampal, R, Rondelli, D, McCaul, K, Brown, R, Komatsu, N, Ohyashiki, K, Ando, K, Kawabata, H, Takenaka, K, Hata, T, Vardiman, J & for the RESUME trialists 2021, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia, vol. 35, no. 4, pp. 1197-1202 . https://doi.org/10.1038/s41375-020-0979-6
Leukemia, 35(4), 1197-1202. Nature Publishing Group
for the RESUME trialists 2020, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia . https://doi.org/10.1038/s41375-020-0979-6, https://doi.org/10.1038/s41375-020-0979-6
Chowdhury, O, O’Sullivan, J, Barkas, N, Wang, G, Buck, G, Hamblin, A, Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, McMullin, M F, Zhong, J, Gale, R P, Mead, A J, Catalano, J, Stevenson, W, Gastl, G, Linkesch, W, Van Droogenbroeck, J, Mineur, P, Gupta, V, Turner, A, Nevill, T, Li, J, Shen, Z, Liu, T, Bordessoule, D, Natarajan-Amé, S, Recher, C, Demory, J L, Schlenk, R, Griesshammer, M, Cazzola, M, Saglio, G, Specchia, G, Rambaldi, A, Pane, F, Zweegman, S, te Boekhorst, P, Raymakers, R, Abdulkadyrov, K, Sokolova, M, Salogub, G, Zaritskiy, A, Cervantes, F, Boluda, J C H, Ojeda, E, Tesfa, D, Nilsson, L, Drummond, M, Reilly, J, Harrison, C, Milojkovic, D, Rivera, C, Besa, E, Deeg, H J, Mascarenhas, J, Prchal, J, Tiu, R, Talpaz, M, Wang, J C, Rampal, R, Rondelli, D, McCaul, K, Brown, R, Komatsu, N, Ohyashiki, K, Ando, K, Kawabata, H, Takenaka, K, Hata, T, Vardiman, J & for the RESUME trialists 2021, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia, vol. 35, no. 4, pp. 1197-1202 . https://doi.org/10.1038/s41375-020-0979-6
Leukemia, 35(4), 1197-1202. Nature Publishing Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0edc47d8d0334cb53e4de6e4bb4f5b9f
http://www.scopus.com/inward/record.url?scp=85089142992&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85089142992&partnerID=8YFLogxK
Autor:
Roman V. Grozov, Tinatin G. Bezhanishvili, Anna Kostareva, Galina Salogub, Sergei V. Lapekin, Victoria G. Davydova, Aleksandr Kulikov, Anzhelika A. Poliakova, Aleksandr N. Krutikov, A Gudkova, Sofiia E. Andreeva, Maria A. Trukshina, Evgenii V. Shlyakhto, Anna A. Streltsova
Publikováno v:
Терапевтический архив, Vol 93, Iss 4, Pp 487-496 (2021)
There are presented the literature data and a description of the clinical course of the disease in isolated/predominant cardiac amyloidosis. Amyloid cardiomyopathy is the most common phenocopy of hypertrophic cardiomyopathy. The modern possibilities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37ec63dd5ef502636848a1bb8d62f5a2
https://ter-arkhiv.ru/0040-3660/article/viewFile/71263/52038
https://ter-arkhiv.ru/0040-3660/article/viewFile/71263/52038
Autor:
Max Topp, Monika Dlugosz-Danecka, Aleksander B. Skotnicki, Galina Salogub, Andreas Viardot, Andreas K. Klein, Georg Hess, Christian S. Michel, Sebastian Grosicki, Alex Gural, Sylvia E. Schwarz, Kerstin Pietzko, Ulrike Gärtner, András Strassz, Leila Alland, Jiri Mayer
Background The prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin’s lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treatment of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0e89131dea4b976b7f85b86b2d5471
https://doi.org/10.21203/rs.3.rs-1113841/v1
https://doi.org/10.21203/rs.3.rs-1113841/v1
Autor:
Vesselina Goranova-Marinova, Eirini Katodritou, Mamta Garg, Michael G. Kauffman, Paul G. Richardson, Lingling Li, Monica Galli, Sosana Delimpasi, Sebastian Grosicki, Jelena Bila, Galina Salogub, Dinesh Kumar Sinha, Holger W. Auner, Larry D. Anderson, Sybiryna Korenkova, Don A. Stevens, Melina Arazy, Reuben Benjamin, Supratik Basu, Jacqueline Jeha, Moshe Yair Levy, Artur Jurczyszyn, Nizar J. Bahlis, Jean Richard Saint-Martin, Jatin P. Shah, Hang Quach, Anna M. Liberati, Tuphan Kanti Dolai, Iryrna Kriachok, Roman Hájek, Anita A. Joshi, Darrell White, Michele Cavo, Sundar Jagannath, Meletios A. Dimopoulos, Xavier Leleu, Hanna Oliynyk, Pawel Robak, Maryana Simonova, Ganna Usenko, Ludek Pour, Maria V. Mateos, Ivan Spicka, Moshe E. Gatt, Atanas Radinoff, Craig T. Wallington-Beddoe, Jeevan Kumar, Vishnuvardhan Peddagali, Halyna Pylypenko, Thierry Facon, Christopher P. Venner, Donna E. Reece, Sharon Shacham, Maria Gavriatopoulou, Yi Chai, Mercedes Gironella, Vadim A Doronin, P. Moreau
Publikováno v:
Lancet (London, England). 396(10262)
Summary Background Selinexor combined with dexamethasone has shown activity in patients with heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor with bortezomib (a proteasome inhibitor) and dexamethasone ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64360017cbcc0f8fe4ee44615eeefcf
https://pubmed.ncbi.nlm.nih.gov/33933202
https://pubmed.ncbi.nlm.nih.gov/33933202
Autor:
Anna Protasova, Lyubov Kuznetsova, Alina Babenko, Olga Irtyuga, Rinat Temirbulatov, Galina Salogub, Darya Yatsenko, Vadim Mazurok, Kseniya Zagorodnikova, Gennadii Trufanov, Yuliya Dolgo-Saburova, Andrei Bautin, Olga Moiseeva, Ofeliya Bettikher, Elena Karelkina, Tatyana Batrakova, Alina Godzoeva, Igor Nesterov, Nadezhda Shabanova, Lyudmila Shirokova, Karina Gabelova
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ddc76e80546a8c5f4a1a42aabfb4034
https://doi.org/10.17816/jowds20202
https://doi.org/10.17816/jowds20202
Autor:
Xavier Leleu, Sundar Jagannath, Reuben Benjamin, Dinesh Kumar Sinha, Jatin P. Shah, Tuphan Kanti Dolai, Veselina S Goranova Marinova, Tadeusz Robak, Monica Galli, Hang Quach, Supratik Basu, Ashraf Z. Badros, Paul G. Richardson, Dane Van Domelen, Craig T. Wallington-Beddoe, Maryana Simonova, Philippe Moreau, Artur Jurczyszyn, Chris Venner, Atanas Radinoff, Sebastian Grosicki, Eirini Katodritou, Roman Hájek, Mercedes Gironella Mesa, Moran Mishal, Yi Chai, Halyna Pylypenko, Sosana Delimpasi, Anna Marina Liberati, Galina Salogub, Jelena Bila, Don A. Stevens, Moshe Yair Levy, Sharon Shacham, Iryna Kriachok, Andrew DeCastro, Mamta Garg, Ohad S. Bentur, Holger W. Auner, Michael Kauffman, Ganna Usenko, Ivan Spicka, Thierry Facon, Maria Gavriatopoulou, Vadim A Doronin
Publikováno v:
Blood. 138:3793-3793
Introduction: Treatment of multiple myeloma (MM) has greatly improved over the last two decades. However, most pts will relapse and develop refractory disease. Most anti-cancer regimens require dose modifications (interruption, reduction, or disconti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75f9f1457870e3b50da70f8952844936
https://doi.org/10.1182/blood-2021-146003
https://doi.org/10.1182/blood-2021-146003
Autor:
Pawef Robak, Victoria Moody, Gabor Mikala, Meletios-Athanasios Dimopoulos, Fredrik Schjesvold, Ivan Spicka, Luděk Pour, Yulia Alexeeva, Galina Salogub, Antonio Lazzaro, Tamás Masszi, Maria-Victoria Mateos, Paul G. Richardson, Vadim A Doronin, Sosana Delimpasi, Daniel Coriu, Catriona Byrne, Vladimir Maisnar, Marcus Thuresson, Wojciech Legiec, Johan Harmenberg, Pieter Sonneveld, Roman Hájek, Jiri Minarik
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S32
Background Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and thereby rapidly releases alkylating agents inside tumor cells. Accelerated approval in the United States of melflufen + dex for p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d91e5baeb03fcacc2d85d357055697
https://doi.org/10.1016/s2152-2650(21)02124-8
https://doi.org/10.1016/s2152-2650(21)02124-8